サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594835

抗うつ薬の世界市場：2024年～2031年

Global Anti-depression Drugs Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗うつ薬の世界市場：2024年～2031年
出版日: 2024年11月21日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

抗うつ薬の世界市場は、2023年に158億1,000万米ドルに達し、2031年には221億米ドルに達すると予測され、予測期間2024年～2031年のCAGRは4.3％で成長します。

抗うつ薬は、気分や感情に関連するセロトニンやノルアドレナリンなどの神経伝達物質と呼ばれる脳内化学物質のレベルを上昇させることによって作用します。抗うつ薬は、大うつ病性障害、不安障害、月経前不快気分障害（PMDD）、双極性うつ病の治療に用いられます。

うつ病の罹患率は世界的に増加しています。このような罹患率の増加は、抗うつ薬の需要を増加させます。例えば、2023年の世界保健機関（WHO）の報告によると、うつ病は人口の約3.8％に影響を及ぼし、そのうち成人の5％（男性の4％、女性の6％）、60歳以上の5.7％が罹患しています。全世界で約2億8,000万人がうつ病を患っています。

市場力学：

促進要因と阻害要因

抗うつ薬の研究開発の増加

抗うつ薬の世界市場は、最近の研究とイノベーションの結果、大きく成長しています。うつ病の罹患率の上昇に伴い、複数の企業や研究機関が多くの調査を実施しています。うつ病は通常、病歴や臨床データ、画像データに基づいて診断されます。

大うつ病性障害の治療における高度な調査とイノベーションが、抗うつ薬市場に貢献する可能性があります。抗うつ薬の開発が進むことで、これらの薬剤の利用可能性が拡大します。例えば、2023年8月、Novartis AGは、治療抵抗性うつ病の治療薬Onfasprodilが臨床開発フェーズIIに入ったと発表しました。オンファスプロジル（MIJ-821）は、大うつ病性障害だけでなく、他の治療に抵抗性のうつ病の治療にも使用されます。

治療薬に関連する副作用

抗うつ薬はうつ病の治療に有効ですが、吐き気、体重増加、性機能障害、ごく一部の患者には自殺念慮のリスク増加などの不快な副作用を引き起こすこともあります。特に特定の患者カテゴリーでは、これらの安全性リスクを注意深くモニタリングし評価する必要があるため、抗うつ薬の使用が制限されることがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 抗うつ薬の調査開発の増加
    • 抑制要因
      • 治療薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • SWOT分析
  • DMIの見解

第6章 薬剤クラス別

  • 選択的セロトニン再取り込み阻害薬（SSRI）
  • モノアミン酸化酵素阻害剤（MAOI）
  • ノルエピネフリン・ドーパミン再取り込み阻害剤
  • セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
  • 三環系抗うつ薬（TCA）
  • セロトニン調節薬
  • その他

第7章 うつ病別

  • 大うつ病性障害
  • 双極性うつ病
  • 強迫性障害
  • 全般性不安障害
  • パニック障害
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Eli Lilly and Company
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Viatris Inc.
  • GlaxoSmithKline Plc.
  • Zheijiang Huahai Pharmaceutical Co. Ltd.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Co. Ltd
  • Pfizer Inc.
  • Aurobindo Pharma Limited
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Other Players

第13章 付録

目次
Product Code: PH8725

Overview

The global anti-depression drugs market reached US$ 15.81 billion in 2023 and is expected to reach US$ 22.10 billion by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

Antidepressant drugs work by increasing levels of chemicals in the brain called neurotransmitters such as serotonin and noradrenaline that are linked to mood and emotion. Antidepressants are used to treat major depressive disorder, anxiety disorders, premenstrual dysphoric disorder (PMDD), and bipolar depression.

There is a growing incidence of depression disorders globally. This increasing incidence increases the demand for anti-depression drugs. For instance, according to the World Health Organization report in 2023, depression affects approximately 3.8% of the population, including 5% of adults (4% among men and 6% among women) and 5.7% of individuals over the age of 60. Approximately 280 million individuals have depression globally.

Market Dynamics: Drivers & Restraints

Increasing research and developments for antidepressant drugs

The global market for anti-depression drugs has grown significantly as a result of recent research and innovations. With the rising incidence of depression disorders, several companies, and research institutes are conducting a large number of studies. Depression is typically diagnosed based on medical history, and clinical and imaging data.

Advanced research and innovations in the treatment of major depressive disorder could contribute to the anti-depression drugs market. The increasing development of anti-depression drugs expands the availability of these drugs. For example, in August 2023, Novartis AG announced that the medication Onfasprodil is in clinical development Phase II for Treatment Resistant Depression. Onfasprodil (MIJ-821) is used to treat depression that is resistant to other treatments as well as major depressive disorder.

Side effects associated with treatment drugs

Antidepressant medicines are effective in treating depression, but they can also cause unpleasant side effects such as nausea, weight gain, sexual dysfunction, and, in a small percentage of patients, an increased risk of suicidal thoughts. The requirement for careful monitoring and evaluation of these safety risks, particularly in certain patient categories, may limit antidepressant drug use.

Segment Analysis

The global anti-depression drugs market is segmented based on drug class, depression disorder, route of administration, distribution channel and region.

Drug Class:

Selective Serotonin Reuptake Inhibitors (SSRIs) segment is expected to dominate the anti-depression drugs market share

Selective Serotonin Reuptake Inhibitors (SSRIs) held a major position in the anti-depression drugs market share and are expected to continue throughout the forecast period. SSRIs have been thoroughly researched and proven to be advantageous in treating depression and anxiety disorders, making them a first-line therapeutic option. SSRIs have a lower risk of side effects than other antidepressants, which leads to higher adherence from patients.

Rising clinical trials on the efficacy and their applications are significant factors for the segment growth. A total of 933 clinical trials have been conducted for depression therapies. For example, on July 13, 2023, the University of Minnesota initiated a clinical trial focused on an Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression. This study aims to assess the effectiveness of two adaptive treatment strategies (ATSs) specifically utilizing SSRIs such as Fluoxetine, Escitalopram, Citalopram, Fluvoxamine, or Sertraline.

Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) segment is the fastest growing segment in the anti-depression drugs market share

Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) segment is at the fastest growing pace in the global anti-depression drugs market. SNRIs offer various advantages over other types of anti-depression drugs such as monoamine oxidase inhibitors. SNRIs have comparatively fewer side effects than other drugs which makes individuals prefer these drugs over other type of anti-depression drugs.

Depression Disorder:

Major depressive disorder segment is expected to dominate the Anti-depression Drugs market share

The major depressive disorder segment is expected to hold the dominant position in the anti-depression drugs market share. This is due to the increasing incidence of the condition. A large number of individuals depend on anti-depression drugs to relieve the condition.

For instance, according to a report published by the National Institute of Health in 2023, it is stated that major depressive disorder is a highly prevalent psychiatric disorder. It has a lifetime prevalence of about 5 to 17 percent, with the average being 12 percent. The prevalence rate is almost double in women than in men.

Bipolar depression segment is the fastest-growing segment in the Anti-depression Drugs market share

The bipolar depression segment is emerging as the fastest-growing segment in the anti-depression drugs market. This growth is driven by the growing incidence of bipolar depression and the rising advancements in the diagnostic procedures for the condition.

Geographical Analysis

North America is expected to hold a significant position in the anti-depression drugs market share

North America has retained a significant portion of the antidepressant medications market in recent years, and this trend is expected to continue during the projection period due to factors such as increased FDA approvals and research and development of anti-depression drugs.

A large number of companies are receiving FDA approvals for their new drugs treating depression disorders, which is contributing to the large anti-depression drugs market expansion. For instance, in August 2022, Axsome Therapeutics, Inc. received FDA approval for AUVELITY (dextromethorphan HBr - bupropion HCl) extended-release tablets. This marked AUVELITY as the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder (MDD) in adults.

Asia-Pacific is growing at the fastest pace in the anti-depression drugs market

Asia-Pacific is experiencing the fastest growth in anti-depression drugs. This is due to the growing incidence of depression disorders and related disorders, and growing awareness among individuals regarding mental health. The region has a large number of pharmaceutical companies which are involved in the production of different drugs including anti-depression drugs.

Competitive Landscape

The major global players in the anti-depression drugs market include Eli Lilly and Company, Viatris Inc., GlaxoSmithKline Plc., Zheijiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. among others.

Key Developments

  • In December 2022, the FDA approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for adult patients with MDD, as reported by AbbVie. Cariprazine, marketed as VRAYLAR in the U.S., is also FDA-approved for treating adults experiencing depressive episodes, acute manic episodes, and mixed episodes associated with bipolar I disorder, alongside schizophrenia.
  • In July 2024, Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).

Why Purchase the Report?

  • To visualize the global anti-depression drugs market segmentation based on drug class, depression disorder, route of administration, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of anti-depression drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global anti-depression drugs market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Depression Disorder
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing research and developments for antidepressant drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with treatment drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Drug Class

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 6.1.2. Market Attractiveness Index, By Drug Class
  • 6.2. Selective Serotonin Reuptake Inhibitors (SSRIs)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Monoamine Oxidase Inhibitors (MAOIs)
  • 6.4. Norepinephrine-dopamine Reuptake Inhibitor
  • 6.5. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
  • 6.6. Tricyclic Antidepressants (TCAs)
  • 6.7. Serotonin Modulators
  • 6.8. Others

7. By Depression Disorder

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 7.1.2. Market Attractiveness Index, By Depression Disorder
  • 7.2. Major Depressive Disorder*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bipolar depression
  • 7.4. Obsessive-compulsive Disorder
  • 7.5. Generalized Anxiety Disorder
  • 7.6. Panic Disorder
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. The U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Viatris Inc.
  • 12.3. GlaxoSmithKline Plc.
  • 12.4. Zheijiang Huahai Pharmaceutical Co. Ltd.
  • 12.5. AstraZeneca Plc.
  • 12.6. Takeda Pharmaceutical Co. Ltd
  • 12.7. Pfizer Inc.
  • 12.8. Aurobindo Pharma Limited
  • 12.9. H. Lundbeck A/S
  • 12.10. Teva Pharmaceutical Industries Ltd.
  • 12.11. Other Players

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us